ABBV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AbbVie Inc (ABBV) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has a promising pipeline and solid revenue growth, the technical indicators and mixed sentiment from analysts suggest a cautious approach. The lack of strong trading signals and recent financial challenges further support a hold recommendation.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 47.548, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest limited short-term upside, with the pivot at 208.34 and resistance at 213.267.
Promising clinical trial results for ABBV-295, a weight loss drug.
Strong pipeline of investigational products, including ABBV-383 for cancer treatment.
Immunology drugs Skyrizi and Rinvoq projected to exceed $31 billion in sales for 2023.
Competitive pressures in the weight loss and immunology markets.
Mixed analyst sentiment and lowered price targets from some firms.
Recent financial performance shows a significant drop in net income and EPS despite revenue growth.
In Q4 2025, revenue increased by 10.04% YoY to $16.62 billion, and gross margin improved to 72.61%. However, net income dropped significantly by -5743.75% YoY to $1.81 billion, and EPS fell by -5200.00% YoY to 1.02, reflecting profitability challenges.
Analysts are mixed on ABBV. Recent ratings include price target reductions from Evercore ISI, Cantor Fitzgerald, and UBS, while Guggenheim and JPMorgan remain optimistic with higher price targets and buy ratings. The overall sentiment is cautious but with potential upside into the Q1 earnings report.
